source
- Tenax Therapeutics’ heart-failure drug misses primary goal in Phase 3 trial, shares tumbleTenax Therapeutics announced that its experimental oral levosimendan failed to meet the primary efficacy endpoint in the Phase 3 LEVEL study, which evaluated treatment for a form of heart failure l…
- Bristol Myers Squibb expands Nvidia partnership to build most powerful AI supercomputer for drug discoveryBristol Myers Squibb announced an expanded partnership with Nvidia that will give it the most powerful and energy-efficient Nvidia infrastructure owned by a life-science company. Nvidia says the p…